Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer ; volume:25 ; number:9 ; day:15 ; month:8 ; year:2024 ; pages:1210-1224 ; date:9.2024
Current treatment options in oncology ; 25, Heft 9 (15.8.2024), 1210-1224, 9.2024
- Classification
-
Medizin, Gesundheit
- Creator
-
Bischoff, Hervé
Espié, Marc
Petit, Thierry
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s11864-024-01251-y
- URN
-
urn:nbn:de:101:1-2412050703220.084795554316
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bischoff, Hervé
- Espié, Marc
- Petit, Thierry
- SpringerLink (Online service)
Other Objects (12)
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Metastatic Triple-Negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Metastatic Triple-Negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer
SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Metastatic Triple-Negative Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis